One of the driving forces in today’s marketplace is intellectual property. Ideas and designs are now as important to corporate success as financial and operational expertise. At Foley Hoag, we understand the value of protecting our clients’ intellectual property; and we have the experience to provide a global perspective. learn more

News more

  • Summer @ Foley Hoag LLPFoley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence  [Read More]
  • Working Mother and Flex-Time Lawyers Recognize Foley Hoag  [Read More]
  • Global Bio-Chem Technology Group Company Limited, Foley Hoag LLP, and Adduci, Mastriani & Schaumberg LLP Prevail in International Trade Commission Patent Infringement Investigation  [Read More]
  • Foley Hoag Joins American Lawyer's Select Group of Top 50 A-List Firms  [Read More]
  • Foley Hoag Files Amicus Brief for Biotechnology Industry Organization  [Read More]

Publications more

  • Economic Crisis Team Datasheet [Read More]
  • Failure to Obtain Opinion of Counsel May Be Evidence of Intent to Induce Infringement [Read More]
  • EEC Perspectives - September 2008 [Read More]
  • Hatch-Waxman Safe Harbor Inapplicable to Research Tools [Read More]
  • Foley Hoag Secures ITC Victory [Read More]

Events more

October 19, 2008 ACC Annual Meeting '08 [Read More] Washington State Convention & Trade Center
Seattle, WA
October 22, 2008 Looking Into The Crystal Ball - How To Prosecute Patents Today That Will Be Enforceable For Twenty Years? [Read More] The Conference Center at WilmerHale
Boston, MA
November 6, 2008 TCN: Funding Expedition™ Mixer [Read More] Foley Hoag LLP (Boston Office)
Boston, MA
November 12, 2008 American Conference Institute’s 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements: Allocating Rights, Responsibilities & Rewards in Licensing, Strategic Alliances and Partnering Deals [Read More] Helmsley Park Lane Hotel
New York, NY

Client Successes more

  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]
  • Advising a Leading Proteomics and Drug Discovery Company
    We represented a proteomics and drug discovery company in connection with a research, development and commercialization collaboration with a company possessing human antibody technology, including the development and commercialization of human antibodies directed against more than 100 different protein targets. Our service to this client has included devising a number of business and legal mechanisms for prioritizing the different protein targets, maintaining commercialization rights in certain fields, and protecting against claims of intellectual property infringement. [Read More]